Critical Decisions in Arrhythmia Management

E. Prystowsky
DOI: https://doi.org/10.1111/j.1540-8159.1990.tb04027.x
1990-11-01
Abstract:The Cardiac Arrhythmia Suppression Trial (CAST) results1 heralded a reevaluation of traditional thinking on the use of certain antiarrhythmic agents. The preliminary results of the study revealed that surprisingly, patients treated after an acute myocardial infarction (AMI) with either of two class IC antiarrhythmic agents (encainide or flecainide) had a higher death rate than placebo-treated patients during a mean of 10 months after initiation of therapy. The increased sudden death rate in patients receiving encainide or flecainide compared with placebo was interpreted as possibly the result of a proarrhythmic propensity of the drugs tested in the recent post-AM1 population. Also, the findings were even more remarkable because both encainide and flecainide successfully suppressed asymptomatic or mildly symptomatic high-grade ventricular arrhythmias in patients after AM1 entered into the study. The implications of the CAST study results with regard to extrapolation to other antiarrhythmic
What problem does this paper attempt to address?